[Correspondence] Is it time to convert the frequency of radiotherapy in small-cell lung cancer?

In June, 2017, Corinne Faivre-Finn and colleagues reported the results of the CONVERT trial,1 which adds great value to management guidance for patients with small-cell lung cancer. They reported that once-daily radiotherapy (66 Gy in 33 fractions) did not differ from twice-daily radiotherapy (45 Gy in 30 fractions) in terms of overall survival (HR 1·18, 95% CI 0·95–1·45; p=0·14), local progression-free survival (1·15, 0·93–1·41; p=0·20), metastatic progression-free survival (1·13, 0·92–1·39; p=0·24), or adverse events in patients with small-cell lung cancer.

http://ift.tt/2fzF1pP